Canadian Consortium on Neurodegeneration in Aging

Overview

Health Research BC and the Canadian Consortium on Neurodegeneration in Aging (CCNA) partner to fund researchers whose work contributes to advancing understanding and care for people living with neurodegenerative diseases. Through this collaboration, we've supported projects that explore how these diseases develop, their impact on individuals and communities, and strategies to slow their progression. The CCNA provides the infrastructure and support that facilitates collaboration amongst Canada’s dementia researchers and clinicians. CCNA is the premier hub for Alzheimer’s disease and dementia research in Canada, and a global leader in research on all aspects of neurodegenerative diseases from prevention to treatment to improving the quality of life of those living with the disease. Canadian clinicians and researchers throughout the country came together to form the Canadian Consortium on Neurodegeneration in Aging (CCNA) in 2014 with the goal of accelerating progress in research on age-related neurodegenerative diseases, including Alzheimer’s disease, Vascular dementia, Frontotemporal dementia, and Lewy body dementia. The Canadian Consortium on Neurodegeneration in Aging (CCNA) entered a third phase of activities in 2024. Research teams across Canada work in the areas of prevention, treatment, and quality of life. They draw on the data of national platforms, and are supported by the Dementia Research Support Hub.
CCNA’s combined expertise will be used to strengthen understanding of:
• How these diseases develop.
• What can be done to slow their progression and cope with them, if not prevent the diseases altogether.
• Their impact on the individual, families, and the community as a whole.
By doing this, CCNA will positively impact the quality of life and the quality of services for individuals living with neurodegenerative diseases. CCNA is a Government of Canada initiative, also supported by several national, provincial and nonprofit organizations.